Scripintelligence - Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer

Science Abstracts

Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
September 2010

Authors : Sharmila Patel , Mark R Player

Affliation : Johnson & Johnson Pharmaceutical Research and Development, Welsh and McKean Roads, Spring House, PA 19477, USA ; ; mplayer@its.jnj.com

DOI : 10.1517/13543780802493366

Published in : Expert Opin. Investig. Drugs

Subject: Review

Keywords: HDM2 , MDM2 , p53 , protein–protein interaction

Abstract

Background: The hdm2...

Please Login to read the full article.

RELATED CONTENT

NEWS Scrip News

Boehringer and Priaxon sign €86 million anticancer pact
Hope high for "personalised medicine" in melanoma
US FDA lays out its position on generic Lovenox as observers ask, is Copaxone next?
Alimera files Iluvien for DMO the US and Europe

Other Informa News

Adaptimmune begins human trials of "holy grail" cellular HIV therapy
PTEN gene status could be marker for aggressive prostate cancer

ANALYSIS Scrip Analysis

Mind over matter - anxiolytics: neuropsychopharmacology's forgotten cousin
Mind over matter - CNS: from Parkinson's to pain

Other Informa Analysis

Gene genie: the role of devices in gene therapy delivery

FEATURES Scrip Features

GW high on pipeline of cannabis extracts
European generics industry throws its weight behind IMPACT

Other Informa Features

Molecular biomarkers – an introduction
Point-of-care testing: the bedside drugs of abuse market